A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
Molecular Neurodegenration; doi: 10.1186/s13024-021-00451-6
